Announced Thu, 9 Apr · 18:05 IST

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹858.95
prior close
₹866.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-1.0-0.9-0.8+0.4+0.9+1.1+2.3+0.9+3.7+0.0+2.5-0.2-4.0
Up moveDown movePending
AI summary

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received a two-day suspension order for a Drug License of its store located at Jadcherla, Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Mahabubnagar, Telangana, under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The order was received on April 8, 2026, and the company filed this update under SEBI regulations. The potential revenue loss from this suspension is estimated at Rs 0.28 lakh (approximately Rs 28,000), which is relatively minor given the company's scale.

Likely market impact

The impact appears limited as the suspension affects only one store for two days with a minimal estimated revenue loss of Rs 0.28 lakh. While it signals a compliance matter at the subsidiary level, the financial impact is not material to Medplus Health Services as a whole.